(Q41472821)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9154280%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

review article

1 reference

title

Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9154280%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

M Diestelhorst

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9154280%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

G K Krieglstein

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9154280%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M Lusky

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9154280%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

S Nagasubramanian

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9154280%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 February 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9154280%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

published in

Survey of Ophthalmology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9154280%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

41 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9154280%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

S77-81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9154280%20AND%20SRC:MED&resulttype=core&format=json

PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. A one-month study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

The ocular pharmacokinetics of eicosanoids and their derivatives. 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF2 alpha, PGF2 alpha-1-methyl ester, and PGF2 alpha-1-isopropyl ester

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

The effects of prostaglandin F2 alpha in the human eye

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

The effect of adding prostaglandin F2 alpha-isopropylester to timolol in patients with open angle glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

PhXA34--a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

Clinical evaluation of UF-021 (Rescula; isopropyl unoprostone).

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6257%2897%2980011-2

7 January 2021

10.1016/S0039-6257(97)80011-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9154280%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference